Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBelluscura Regulatory News (BELL)

Share Price Information for Belluscura (BELL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.50
Bid: 8.00
Ask: 9.00
Change: 0.50 (6.25%)
Spread: 1.00 (12.50%)
Open: 8.00
High: 8.50
Low: 8.00
Prev. Close: 8.00
BELL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Distribution Agreement & New VP North America

13 Feb 2024 07:00

RNS Number : 8870C
Belluscura PLC
13 February 2024
 

13 February 2024

 

Belluscura plc

("Belluscura" or the "Company")

 

Belluscura announces implementation of distribution agreement with Sunset HealthCare Solutions

New Vice President of North American Sales

 

Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces a new partnership with Sunset HealthCare Solutions ("Sunset Healthcare") and the promotion of Konstantin Grey to Vice President of North American Sales.

 

Sunset HealthCare is a Chicago-based manufacturer and distributor of Home Medical Equipment ("HME") supplies offering an extensive range of quality HME products, innovative solutions and specialised product support. It partners with over 1,600 healthcare businesses, serving all of the United States alongside key international accounts. Sunset Healthcare has a network of sales representatives extending across the US and in 150 countries around the globe.

 

Under the distribution agreement, Sunset HealthCare will offer the X-PLOR® portable oxygen concentrator ("POC") to over 1,600 customers. It is intended that the agreement will be extended to also include distribution of the award winning DISCOV-R? POC in Q2 2024 when the product becomes available to Durable Medical Equipment ("DME") suppliers.

 

Belluscura also announces that Konstantin Grey has been appointed Vice President of North American Sales. Having joined Belluscura in July 2023, Konstantin has been responsible for the creation and launch of Belluscura's direct to consumer sales force and website, which has seen strong growth in sales and gross margins since its launch last year. He also successfully launched our unique direct to consumer leasing program and has been instrumental in driving this new partnership with Sunset HealthCare, as well as a healthy pipeline of further opportunities. Konstantin has 15 years of experience in the DME industry, including having founded and subsequently sold his own DME company.

 

Robert Rauker, Chief Executive Officer, Belluscura plc, said:

 

"We welcome the new partnership with Sunset HealthCare Solutions, which will provide over 1,600 healthcare businesses with access to our innovative products through a trusted, industry leader. This agreement significantly expands our distribution network."

 

PJ Ruflin, VP Business Development, Sunset Healthcare Solutions, stated:

 

"Sunset Healthcare Solutions is committed to finding great products and partners to support our customers and their patients. Our partnership with Belluscura offers a unique opportunity to bring meaningful innovation and support to the market at a critical time."

 

Bob Fary, Senior Vice President of Global Sales, commented:

 

"Konstantin has been a tremendous asset since joining Belluscura, as demonstrated by his ability to bring on partners like Sunset Healthcare Solutions. In his new role as VP of North America, Konstantin is set to further drive Belluscura's mission of enhancing patient quality of life through innovative, accessible healthcare solutions. We look forward to building on our success to date as we launch our next generation molecular sieve technology and DISCOV-R."

 

END

 

For further information, please contact:

 

Belluscura plc

www.belluscura.com

Robert Rauker, Chief Executive Officer

via MHP

Simon Neicheril, Chief Financial Officer

SPARK Advisory Partners Limited (NOMAD)

Tel: +44 (0)20 3368 3550

Neil Baldwin / Jade Bayat

Dowgate Capital Limited (Broker)

Tel: +44 (0)20 3903 7715

James Serjeant / Nicholas Chambers

MHP Communications (Financial PR and Investor Relations)

Tel: +44 (0)20 3128 8100 / +44 7884 494112

Katie Hunt / Matthew Taylor

Email: belluscura@mhpgroup.com

 

 

About Belluscura plc ( www.belluscura.com )

Belluscura is a UK medical device company focused on developing high performing, lightweight and portable oxygen enrichment technology used in a broad range of industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health, mobility and economic outcomes for patients, healthcare providers and insurance organisations.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGREAEAAFDKLEAA
Date   Source Headline
8th Nov 202311:44 amRNSForm 8.3 - Belluscura PLC
7th Nov 20233:35 pmRNSForm 8.3 - TMT Acquisition PLC
2nd Nov 20236:15 pmRNSForm 8.3 - TMT Acquisition
2nd Nov 20234:23 pmPRNForm 8.3 - Belluscura Plc
1st Nov 20233:03 pmRNSReplacement: Rule 2.7 Announcement
31st Oct 20234:52 pmRNSRule 2.7 Announcement
27th Oct 202312:23 pmGNWForm 8.3 - Belluscura Plc
25th Oct 20237:00 amRNSStatement regarding possible offer
24th Oct 20238:26 amRNSForm 8 (OPD) TMT (offeree) re TMT
24th Oct 20238:15 amRNSForm 8 (OPD) TMT (offeree) re Belluecura PLC
24th Oct 20237:00 amRNSForm 8 (OPD) Belluscura plc
24th Oct 20237:00 amRNSForm 8 (OPD) TMT Acquisition PLC
24th Oct 20237:00 amRNSBelluscura Launches Direct to Consumer Program
19th Oct 20234:09 pmRNSForm 8.3 - TMT Acquisition PLC
19th Oct 20234:02 pmRNSForm 8.3 - Belluscura PLC
18th Oct 20233:19 pmRNSForm 8.3 - Belluscura plc
18th Oct 20231:38 pmRNSForm 8.3 - Belluscura plc
18th Oct 202311:54 amRNSForm 8.3 - Belluscura plc
17th Oct 20233:22 pmRNSForm 8.3 - Belluscura plc - Replacement
17th Oct 20233:12 pmRNSForm 8.3 - Belluscura PLC
17th Oct 20232:56 pmRNSForm 8.3 - Belluscura plc
17th Oct 20238:20 amRNSForm 8.3 - TMT Acquisition PLC
17th Oct 20237:30 amRNSForm 8.3 - Belluscura plc
17th Oct 20237:00 amRNSForm 8.3 - Belluscura plc
16th Oct 20235:14 pmRNSForm 8.3 - BELLUSCURA PLC
16th Oct 20235:09 pmRNSForm 8.3 - BELLUSCURA PLC
16th Oct 20232:00 pmRNSForm 8.3 - Belluscura Plc
16th Oct 20239:44 amRNSForm 8.3 - Belluscura plc
16th Oct 20239:42 amRNSForm 8.3 - Belluscura plc
16th Oct 20237:00 amRNSTakeover Code Form 8.3 - Belluscura plc
16th Oct 20237:00 amRNSForm 8.3 - Belluscura plc
13th Oct 20236:13 pmRNSForm 8.3 - TMT Acquisition plc
13th Oct 20236:10 pmRNSForm 8.3 - Belluscura plc
13th Oct 20236:08 pmRNSForm 8.3 - TMT Acquisition plc
13th Oct 20236:02 pmRNSForm 8.3 - Belluscura plc
13th Oct 20235:59 pmRNSForm 8.3 - TMT Acquisition plc
13th Oct 20235:55 pmRNSForm 8.3 - Belluscura plc - Replacement
13th Oct 20235:52 pmRNSForm 8.3 - Belluscura plc
13th Oct 20234:21 pmRNSForm 8.3 - Belluscura plc
13th Oct 20234:19 pmRNSForm 8.3 - Belluscura PLC
12th Oct 20233:23 pmRNSForm 8.3 - TMT Acquisition plc
12th Oct 20233:01 pmRNSForm 8.3 - TMT Acquisition plc
12th Oct 20232:47 pmRNSForm 8.3 - TMT Acquisition plc
12th Oct 202312:42 pmBUSForm 8.3 - Belluscura plc
12th Oct 20239:55 amRNSForm 8.3 - BELLUSCURA PLC
11th Oct 20234:20 pmRNSForm 8.3 - Belluscura PLC
10th Oct 20235:10 pmRNSForm 8.3 - TMT ACQUISITION PLC
10th Oct 20235:09 pmRNSForm 8.3 - [BELLUSCURA PLC]
10th Oct 20234:40 pmRNSForm 8.3 - Belluscura PLC
10th Oct 20234:21 pmRNSForm 8.3 - BELLUSCURA PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.